Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.

Beattie, David T; Pulido-Rios, M Teresa; Shen, Fei; Ho, Melissa; Situ, Eva; Tsuruda, Pam R; Brassil, Patrick; Kleinschek, Melanie; Hegde, Sharath.

Afiliação

Beattie DT; Department of Pharmacology , Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Pulido-Rios MT; Department of Pharmacology , Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Shen F; Department of Pharmacology , Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Ho M; Department of Biology, Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Situ E; Department of Biology, Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Tsuruda PR; Department of Pharmacology , Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Brassil P; Department of Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Kleinschek M; Department of Biology, Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.
Hegde S; Department of Pharmacology , Theravance Biopharma US, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080 USA.